×

RNS Number : 7231K

Genedrive PLC

24 April 2020

 

genedrive plc

("genedrive" or the "Company")

 

Distribution agreement for AIHL test

 

 Inspiration Healthcare to distribute genedrive's Antibiotic Induced Hearing Loss test in UK & Ireland

Option to expand agreement to engage Inspiration Healthcare's global neonatal sub-distributor network

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into a contract for the distribution of the Company's Antibiotic Induced Hearing Loss test (Genedrive® MT-RNR1) in the UK and Ireland with Inspiration Healthcare Group plc (AIM: IHC) ("Inspiration Healthcare"). The companies also expect to expand the scope of the contract over time to engage Inspiration Healthcare's specialty network of over 50 neonatal focussed sub-distributors around the world.

 

David Budd, Chief Executive Officer of genedrive plc, said: "Our agreement with Inspiration Healthcare combines genedrive's innovative first-to-market AIHL product, with a thought leading healthcare company with a specialist emphasis on neonatal care. Inspiration Healthcare has a strong track record in the introduction of new technologies and over many years they have developed an extensive network of key opinion leaders that will be very beneficial as we bring the Genedrive AIHL test to market together."

 

The Genedrive ® MT-RNR1 test is the world's first point-of-care genetic test designed for use in a neonatal intensive care setting. The test screens newborns for a genetic mutation called mt-RNR1 that can cause lifelong and irreversible deafness to a child upon administration of certain antibiotics.   In the UK, 90,000 babies are admitted to NICU units each year, and 80-85% of them receive antibiotics. Genedrive's rapid genetic test can be completed in less than 30 minutes, allowing for correct treatment decision on antibiotics to be made within one hour of admission, as required by the UK's National Institute of Clinical Excellence (NICE).

 

Neil Campbell, Chief Executive Officer of Inspiration Healthcare, commented : "We are delighted to be able to work with genedrive plc with this novel testing device for new born babies that could suffer hearing loss due to antibiotics given to them on admission into neonatal intensive care. Our focus has always been products that can have a profound effect on the patient outcome and we look forward to working with genedrive to make this test the standard of care in the UK and the wider neonatal community around the world."

genedrive plc	+44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser and Joint Broker)	+44 (0)20 7418 8900
James Steel / Oliver Jackson
finnCap Ltd	+44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice Lane
Walbrook PR Ltd (Media & Investor Relations)	+44 (0)20 7933 8780 or [email protected]
Paul McManus / Anna Dunphy	+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc ( http://www.genedriveplc.com )

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, Antibiotic Induced Hearing Loss, and has tests in development for tuberculosis (mTB) and SARS-CoV-2.

 

 

About Inspiration Healthcare (http://www.inspiration-healthcare.com)

 

Inspiration Healthcare is a global provider of medical technology for use in critical care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.

 

Through investment in research and development the Company has 6 key own brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally the Company has its own range of products for maintaining normothermia pre- during and post-surgery.

 

With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe. In the UK and Ireland the Company has a direct sales team selling Inspiration Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

AGREAELDAASEEAA

Close

×

RNS Number : 7167K

N4 Pharma PLC

24 April 2020

 

24 April 2020

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

New Nuvec® opportunity and patent filing

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that it has filed a new UK patent application around both Nuvec®'s ability to be used to manufacture viral vectors and to make viral vectors more efficient in applications such as ex-vivo gene therapy treatments.

 

Nuvec® has a unique structure that allows the easy loading of DNA plasmids. The manufacture of viral vectors typically requires the use of two or more plasmids. Nuvec® has been shown to be capable of loading multiple plasmids. In recent research conducted by the Company, it has been demonstrated that loading Nuvec® with the three plasmids typically used to produce lentivirus, resulted in an increase in the amount of the desired viral vector produced.  The manufacture of viral vectors is an expensive process, so utilising Nuvec®'s ability to efficiently load and deliver multiple plasmids could greatly reduce the cost involved in this process.

An important use of viral vectors is in ex-vivo gene therapy. In this approach, a patient's cells are taken from their body and more are grown in the laboratory. Whilst still outside the body, these cells are modified by adding the gene of interest into the cells' DNA by using viral vectors that are carrying the gene. These cells, carrying the gene designed to treat the patient, are then re-inserted back into the patient's body. In separate research, the Company has demonstrated that when complexed with a lentivirus carrying a gene of interest, Nuvec® can be used as a reagent to produce cells containing the gene using a fraction of the original lentivirus, thereby suggesting that this process can be made cheaper and more efficient.

The Company is now working with external consultants to identify how best to enter the virus manufacture and ex-vivo gene therapy markets .

 

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"Whilst investigating the dispersion of Nuvec® to improve its in-vivo consistency, we have been undertaking research on the in-vitro applications of Nuvec® as all our data shows good and consistent loading and in-vitro transfection using Nuvec®.

 

"The global viral vector manufacturing market was valued at $273 million in 2017 and is expected to grow to $816 million by 2023 . Sales of transduction reagents were estimated to be $68m in 2017 and growing to $123m by 2024.

 

"These are significant markets for in-vitro applications of Nuvec® and will allow us to look at additional commercial opportunities whilst we continue to develop our in-vivo data package for licensing Nuvec® as a delivery system for cancer treatments and vaccines. "

 

 

Enquiries:

 

N4 Pharma Plc Nigel Theobald, CEO	Via Scott PR
Allenby Capital Limited James Reeve/Asha Chotai	Tel: +44(0)203 328 5656
Scott PR Georgia Smith	Tel: +44(0)1477 539 539

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCSESFMDESSEIL

Close

×

Neville Registrars is delighted to welcome ABEO Investments Limited as the newest addition to its list of client companies.

ABEO Investmentsis a newly formed Residential Property Investment Company.

Further information can be found on the Company's website: http://www.abeoinvestments.co.uk/

Close

×

RNS Number : 4692J

DeepMatter Group PLC

14 April 2020

 

14 April 2020

RNS Reach

DeepMatter Group plc

("DeepMatter", the "Company" or "the Group")

 

DeepMatter's technology selected by Cancer Research UK Beatson Institute

Cancer Research UK Beatson Institute to trial DigitalGlassware™ within its Drug Discovery Unit to enhance the reproducibility of its chemistry and accelerate drug discovery

 

14 April 2020 – DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry has signed a contract with the Cancer Research UK Beatson Institute and Cancer Research Technology (the commercialisation and development arm of Cancer Research UK) for its DigitalGlassware™ platform. The technology will be installed within the institute's Drug Discovery Unit to enable the accurate and reproducible sharing of its research output with its outsourced chemistry partners located in China. The use of DigitalGlassware™ means the Drug Discovery Unit will be able to share its cutting-edge chemistry across locations, so that work is not needlessly duplicated nor time and money wasted, and ultimately so new discoveries might be made faster. 

 

The DigitalGlassware™ platform will allow the Drug Discovery Unit to accurately and systematically record, code and enter the results of their experiments into a shared data cloud, enabling the sharing of details of their experiments from anywhere and in real-time.

 

A subsequent deployment in China is anticipated to take place later in 2020.

 

Mark Warne, CEO of DeepMatter Group, commented: "We are very proud to be working with Cancer Research UK Beatson Institute, one of Europe's leading cancer research centres, and delighted that through the use of our technology, DeepMatter is able to support them in their life-saving work.

 

"The difficulty in consistently reproducing quality chemistry globally is an issue that continues to plague chemists. DigitalGlasswareTM addresses this problem and we believe it has the potential to transform the industry ."

 

Justin Bower, Joint Head of the Drug Discovery Unit and Head of Chemistry at the Cancer Research UK Beatson Institute, added: "We know that improved reproducibility in our work, particularly when achieved across multiple sites, will lead to enhanced productivity and a faster speed of discovery. DeepMatter's technology is some of the most innovative we have seen to date and we look forward to working with them test its capabilities."

 

For more information, please contact:

DeepMatter Group plc	T: 0141 548 8156
Mark Warne, Chief Executive Officer
C anaccord Genuity Limited (Nominated Advisor and Broker)	T:  020 7523 8000
Bobbie Hilliam / Angelos Vlatakis
Alma PR Caroline Forde / Susie Hudson / Harriet Jackson	T: 020 3405 0205 [email protected]
Cancer Research UK Beatson Institute	T: 0141 330 3953
Head of Chemistry/Joint Head of BDDU, Justin Bower

 

About DeepMatter Group plc  

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware™, to scientists across research and process development sectors. 

 

The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster. 

 

Visit: www.deepmatter.io and follow @deepmattergroup 

 

Cancer Research UK Beatson Institute

The Cancer Research UK Beatson Institute in Glasgow, directed by Professor Owen Sansom, is one of Europe's leading cancer research centres, supporting cutting-edge work into the molecular mechanisms of cancer development. As well as core support from Cancer Research UK, the Institute also receives income from a number of external grants and industry collaborations. The Beatson has an excellent reputation for fundamental cancer research, including world-class metabolism studies and renowned in vivo modelling of tumour growth and metastasis. Its Drug Discovery Unit, headed by Justin Bower and Heather McKinnon, is central to its mission to apply cancer discovery for patient benefit. www.beatson.gla.ac.uk .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAIJMLTMTABBFM

Close

×

RNS Number : 9599H

British Honey Company PLC (The)

30 March 2020

 

30 03 2020

 

The British Honey Company plc

 

('British Honey', 'BHC' or the 'Company')

 

Corporate Update

 

Strategic Collaboration to provide BHC with access to £65 Billion US spirits market;

Operational focus moving to market-ready brands and production of Alcohol Sanitiser;

Termination of JV to develop new product

&

Multiple International Awards at 25th Annual San Francisco World Spirits Competition

 

British Honey, the premium British Honey and Infused Spirits brand, is pleased to provide the following corporate update.

 

 

Collaboration with List Distillery of the US

 

The Company is pleased to announce a strategically important collaboration agreement with List Distillery LLC ("List"), based in Florida, USA. Under the new Agreement, BHC and List will collaborate to develop a broader market for each of the Company's existing products. BHC will supply List with high concentrate London Dry Gin, which will be bottled and marketed by List under the Keepr's brand in the US.

 

The Agreement gives BHC access to List's extensive distribution network which covers more than 12 States across the US, a highly cost-effective way of market entry given the fragmented nature of the retail spirits market there. BHC has already identified the US, which has an estimated spirits market by value of over £65 billion annually, as one of two key territories where it is looking to focus its overseas marketing efforts, the other being China.

 

BHC and List already have an established trading relationship, with BHC purchasing List's bourbon, American whiskey and rum which it bottles and sells in the UK under the Keepr's brand, while List's proprietary "Mr Tom's" Spirits Collection of premium vodka, gin, rum and whiskey, are renowned for their quality, using all-natural and locally sourced ingredients.

 

Both parties recognise the significant growth opportunities for premium craft distillers, with customer preferences increasingly favouring specialist artisan spirits over large global brands. List will use its expertise and experience of the US market to promote BHC's proprietary brands. BHC will use its master distiller to enhance List's imported Rum, American Whiskey and Bourbon to suit the UK market.

 

BHC and List have been working together to develop Alcohol Sanitiser and are now supplying medical services in both Florida and the United Kingdom. All spare production capacity at both distilleries has been turned over to the manufacture of this product.

 

As a result of its collaborative work with List Distillery, BHC is delighted to announce that, at the 2020 San Francisco World Spirits Competition held earlier this month, the following products were awarded medals:

 

Keepr's Smoked Honey Bourbon   Gold

Keepr's Honey Spiced Rum   Bronze

Keepr's Classic London Dry Gin with British Honey   Silver

 

These new products will be sold in the United States and UK.

 

 

Alcohol Sanitiser

 

Following the announcement on 17 March 2020 that BHC had been granted HMRC authorisation to produce denatured 70% ABV Alcohol Sanitiser, BHC has successfully launched its "Drip+Drop" Alcohol Sanitiser product.  Initial orders of the product have been particularly strong due to the shortage of sanitiser product in the UK caused by the COVID-19 outbreak.  The Company is currently using spare capacity in the UK to manufacture alcohol sanitiser but is also exploring methods of producing an active alcohol sanitiser.

 

 

Distil Joint Venture

 

More generally, the COVID-19 outbreak has caused the Company to review its operational focus given its impact on the distribution channels available to the Company. As a result, the board has determined that the Company's main focus will now be on market-ready or near market-ready alcoholic beverages and sanitiser. Accordingly, the Company has considered that the development of untested alcoholic products is not an operational priority at the present time and has therefore served notice on Distil plc (AIM: DIS) to terminate its joint venture agreement to produce a new botanical vodka.  No funds have yet been expended developing this new product under the joint venture.  The Company remains committed to the development of further new products in the future.

 

 

Further International Awards

 

The Company is delighted to announce that, at the 2020 International Spirits Challenge, held earlier this month, the following product was awarded a medal:

 

Keepr's British Sloe and British Honey Gin

Silver

 

 

Michael Williams, BHC CEO, commented:

 

"As part of our planned international sales drive and expansion I am delighted to announce this strategically important Collaboration Agreement with List, further developing our trading relationship. It will enable us to extend our global reach and take advantage of significant growth opportunities in the US. The team at List are renowned distillers with excellent knowledge of the infused spirits market in their home country. Meanwhile, both Distilleries are co-operating in the manufacture of alcohol sanitiser. Daily conference calls between the respective management teams are taking place, sharing experiences and product modification, demonstrating the already close affiliation we enjoy.

 

Whilst we are disappointed to have to put on hold the development of new drinks products, our energies must now be devoted entirely to market-ready or near market-ready products. This includes the production and supply of alcohol sanitiser as part of our programme to support the NHS and other institutions in need of immediate supply. BHC have enlisted the help of Dr George Tranter of Chiralabs Limited, Oxford, in exploring the development of new products that will help in this national emergency.

 

I would also like to take this opportunity to thank all of our staff and, particularly, Jamie Baggott, our Master Distiller, and Thomas List for the fantastic results at the San Francisco World Spirits Competition this year. This is further recognition of quality of our Keepr's and List Spirits"

 

Thomas List, President and owner of List Distillery added:  

 

"We at List Distillery are very happy to have found a business partner like BHC which shares our passion and enthusiasm for the opportunities existing in the global spirits market. Besides our common business strategies, we also share similar values in wanting to give something back to our communities by jointly producing Alcohol Sanitiser, donating to the public and supplying the medical community.

 

We believe this Collaboration will allow us both to exponentially grow our respective businesses."

 

 

The Directors of the Company take responsibility for this announcement.  This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Enquiries: 

BHC  Brooke Wiseman, Marketing Director	Tel: +44 (0)7976 559243 Email: [email protected] Web: https://britishhoney.co.uk/
Cairn Financial Advisers  Jo Turner / Mark Rogers	Tel: +44 (0)20 7213 0885
Stanford Capital Partners  Patrick Claridge / John Howes / Bob Pountney	Tel: +44 (0)20 3815 8880
Trade Press Enquiries  Jellybean Creative Solutions  Neil Brenson	Tel: +44 (0)1372 220 814 Email: [email protected]

 

 

Notes to Editors

 

About British Honey Company

Launched in 2014, BHC is famed for its award-winning fruit and honey infused spirits, marketed under the Keepr ' s brand. Many of the Keepr ' s spirits are infused with BHC ' s proprietary British Honey from its fully traceable apiaries. The impressive spirits range with seasonal lines spans eight gins, four vodkas, two rums, two bourbons and a whiskey which is scheduled for release  in 2022. All of BHC ' s spirits are distilled onsite in the company ' s specially customised Still under the watchful eye of international award-winning Master Distiller, Jamie Baggott.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NEXSESESUESSELD

Close

×

RNS Number : 9509H

Integumen PLC

30 March 2020

 

AIM share code: SKIN

30 March 2020

 

Integumen PLC

 

("Integumen" or "Company")

 

Immediate production of bacteria to detect water contamination amid COVID-19 public health crisis

 

Integumen confirm c£2m confirmed orders in Q1, 2020 and invests £250,000 to ramp-up production

 

Integumen announces that due to the global COVID-19 public health crisis, and in order to meet back-orders and growing demand for water contamination detection bacteria from existing customers across Spain, Italy and China, production of Modern Water's monitoring bacteria reagent has commenced this week, six weeks ahead of the originally planned production date.

 

Further to previous notifications, enlargement of Integumen's laboratories and fit-out has commenced with the ordering of the new laboratory equipment. The bacteria is used in fixed and portable monitoring equipment, designed and manufactured by Modern Water plc to identify contamination in wastewater outlets from residential, hospital and municipal sewage treatment outflows that may contribute to the current public health crisis.

 

In addition to the c£2m of confirmed orders so far in Q1, 2020 for delivery in the current financial year, Integumen is investing £250,000, as announced in the RNS of 18 March  2020, to rapidly expand the Company's laboratories by 100% to 6,000 square feet in order to maintain the growth of Labskin and accelerate production of bacteria that is used by a range of monitoring equipment for the detection of up to 2,300 bacteria, viruses and toxins that contaminate water around the world.

 

Gerard Brandon CEO Integumen plc commented:

"In the wake of the COVID-19 public health crisis, we are grateful to local industry and research institutions such as Frozen in Time Limited and University of York, who have enabled Integumen to begin production immediately. We are now able to bring water contamination detection bacteria faster to the frontline environmental inspection teams, in crisis countries, where there is currently insufficient supply. I also want to acknowledge our team of dedicated chemical engineers, biologists, microbiologists and quality control personnel who are playing their role in making this happen.

 

"Integumen is in a strong position to provide the support for Modern Water and all their customers across the world through delivery of integrated engineering, scientific and real-time data analytical solutions in order to address this major societal and global problem in healthcare and the environment. "

 

 

Integumen plc	Gerard Brandon, CEO	+44 (0) 7340 055 648
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/Zoe Alexander	+44 (0) 20 3657 0050

 

About Integumen plc

Integumen is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 10 global cosmetic company clients to remotely detecting water contamination in real-time.

 

About Modern Water plc

Modern Water was established in 2006 to develop and commercialise water recovery technologies to counter water crisis problems arising from climate change and a growing global population. Having invested £20m over the last 14 years, the results comprise of a robust patent portfolio of cutting edge technology, focused on monitoring of contaminated water and decontamination of wastewater, making recycling of water more efficient. Six countries across the world have legislated that Modern Water monitoring test systems are written into their environmental protection legislation. 

 

About Frozen in Time

Based in York, UK, Frozen in Time Limited has been designing and manufacturing freeze dryers for more than a quarter of a century. In that time, they fabricated machinery in a full range of sizes and specifications, for businesses of all sizes, working in all kinds of industry sectors worldwide.

 

About University of York

The University of York is a collegiate research university, located in the city of York, England. Established in 1963, the university has expanded to more than thirty departments and centres. With over £8 million of capital equipment, 2,000 square meters of laboratories, the purpose-built centre of excellence provides access to state-of-the-art bioscience technologies for external academic laboratories and commercial business users. It has all the relevant equipment needed to begin production of the water contamination detection bacteria immediately.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

UPDUWVWRRKUOURR

Close

×

RNS Number : 7738H

Shearwater Group PLC

27 March 2020

 

RNS Reach

 

27 March 2020

 

SHEARWATER GROUP PLC

 

Contract Win

 

Shearwater Group plc, the organisational resilience group, announces that its group company, GeoLang, has won a new three-year contract worth circa £0.2 million in aggregate with a leading global medical and research development organisation, specialising in oncology and DNA / RNA sequencing.

 

Under the terms of the contract GeoLang will provide the organisation with Cloud Data Loss Prevention ("DLP") as well as Data Discovery and extraction solutions that cross the boundaries between Office 365, Box and Confluence.

 

While there are many tools on the market that offer network DLP, these tools will often have gaps in the cloud solutions that they protect with no true endpoint visibility. GeoLang is able to provide agile development capabilities, connecting the dots that extend its Ascema DLP and Data Discovery platform to offer real time discovery and protection of sensitive data and IP across legacy and disparate enterprise systems.

 

Phil Higgins, Chief Executive Officer of Shearwater, commented:

 

"This is a great contract win for GeoLang. To be partnering with a prestigious organisation specialising in highly regulated and complex fields including human genomics, cancer research and microbiology, is a great reflection of the capability of GeoLang's patented software in mitigating risk and the loss of invaluable data and information.

 

"It is also pleasing to see the benefit of the investments made in developing GeoLang's proprietary software suite gaining traction as the business begins to scale."

 

Enquiries:

 

Shearwater Group plc David Williams, Chairman Phil Higgins, Group CEO	c/o Instinctif Partners
Instinctif Partners Adrian Duffield / Chantal Woolcock	[email protected]   +44 (0) 20 7457 2815

 

About Shearwater Group plc

 

Shearwater Group plc is an award-winning organisational resilience group that provides cyber security, advisory and managed security services to help assure and secure businesses in a connected global economy.

 

The Group's comprehensive cyber security solutions and services maintain trust between users, provide assurance around the protection of information assets and critical infrastructure, and support organisations' operational effectiveness.  Its capabilities include identity and access management and data security, cyber security solutions and managed security services, and security governance, risk and compliance.

 

The Group is headquartered in the UK with offices in the US, UK and Europe, serving customers across the globe who are active in a broad spectrum of industries.

 

Shearwater shares are listed on the London Stock Exchange's AIM under the ticker "SWG".  For more information, please visit www.shearwatergroup.com.

 

 

About GeoLang

 

GeoLang delivers data discovery and data loss prevention solutions, services and technologies to discover, classify and protect sensitive data and information in the cloud and on-premise.  For more information, please visit www.geolang.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAKKABNABKDANB

Close

×

RNS Number : 8403H

Gresham House PLC

27 March 2020

 

 

27 March 2020

Gresham House plc

("Gresham House", the "Company" or the "Group")

New Investment Management Contract – Strategic Equity Capital plc

Gresham House (AIM: GHE), the specialist alternative asset manager, is pleased to announce that Gresham House Asset Management ("GHAM") has been appointed as the investment manager and Alternative Investment Fund Manager ("AIFM") of Strategic Equity Capital plc ("SEC").

On completion of Gresham House's proposed joint venture with Aberdeen Standard Investments ("ASI",) Aberdeen Standard Gresham House Investment Management Limited ("Aberdeen Standard Gresham House"), a company to be jointly owned by Gresham House and ASI will ultimately become, subject to regulatory and other approvals, SEC's investment manager and AIFM.

SEC was launched by SVG Investment Managers Limited ("SVGIM") in 2005 with a distinctive investment strategy to apply private equity techniques to public equities. At the time of its launch, SVGIM was led by Gresham House CEO Anthony (Tony) Dalwood, supported by a broad private equity platform.

Gresham House's joint venture with ASI, acting through Aberdeen Asset Management plc, was announced in March 2019.  Gresham House was selected by ASI as a joint venture partner on the basis of its long, successful track record investing in the strategic public equity space. The intention of the joint venture is to grow the strategic public equity ("SPE") platform and opportunity. This specialist philosophy to investing involves a highly engaged approach using private equity techniques to investment in smaller public companies.

For Gresham House, the joint venture represents an opportunity to focus on its core investment process while ASI's responsibility will be to bring its strong investment company sales and marketing capabilities to increase assets under management. The appointment of GHAM and ultimately Aberdeen Standard Gresham House, has the following key benefits:

· A strong and well-established platform (£3bn AUM as at March 2020) with a strong net cash balance sheet and well-developed operational resources. It has an established pedigree of investing on a strategic public equity ('SPE') basis in UK equity markets, which has been recognised by Aberdeen Standard Investments.

· A team-based capability led by Tony Dalwood, based on his 20 years of investment experience in the strategy, including the period of time when he led SVGIM. Since 2015, this strategy has been deployed by Gresham House. The SEC investment process will follow the Gresham House SPE investment process.

 

· An Investment Committee with broad experience across the industry, comprising, Tony Dalwood (Chair of the Investment Committee), Peter McKellar (ASI's Global Head of Private Markets) following completion of the joint venture, Richard Staveley  (Managing Director of SPE at Gresham House), Ken Wotton (Managing Director of Public Equities, Gresham House) and three external members (Tom Teichman, Bruce Carnegie-Brown and Graham Bird).
 

· The strong investment company sales and marketing capabilities of ASI, which will be leveraged through the joint venture. ASI manages 24 investment companies, with aggregate total assets of £10.3bn as at 29 February 2020, which all benefit from a dedicated investment company sales and marketing capability
 

· Gresham House and funds managed by ASI intend through reasonable endeavours to acquire a significant number of shares in the Company through the secondary market over the medium-term following the appointment of Aberdeen Standard Gresham House as the new Investment Manager.

Commenting, Tony Dalwood, Gresham House's Chief Executive & Chairman of the SPE Investment Committee, said:

"We are delighted to be appointed investment manager of Strategic Equity Capital plc working together with Aberdeen Standard Investments. We have complementary skills in our strategic public equity ("SPE") approach to smaller companies investment and our shared expertise will create long-term shareholder value for Strategic Equity Capital.  We look forward to working with the SEC Board to manage the existing portfolio and to strengthening the investment process to ensure its long-term success."

Richard Hills, Chairman of SEC, said:

"Following a detailed review, initiated at the end of last year, the Board of Strategic Equity Capital is pleased to announce that it has signed heads of terms to appoint a new investment manager. Notwithstanding that we are in the midst of extreme market turbulence, we believe that the change is beneficial for shareholders. Indeed, we believe that Aberdeen Standard Gresham House has the experience, the platform and the associated investment management infrastructure to enhance the delivery and marketability of our investment strategy in these challenging times."

Peter McKellar, Global Head of Private Markets of Aberdeen Standard Investments, commented:

  "We are delighted that the Board of Strategic Equity Capital plc will be appointing Aberdeen Standard Gresham House as its new Investment Manager. We selected Gresham House as our joint venture partner in recognition of their deep and specialist expertise in this strategy and ability to identify compelling opportunities and generate attractive returns."

Further details

The incumbent SEC management team of Jeff Harris and Adam Khanbhai will transfer to the new manager team and be part of the SPE team reporting to the SPE Investment Committee chaired by Tony Dalwood.

The joint venture will be based on the Gresham House platform and continue to benefit from the connectivity to other equity investment teams and the full investment management infrastructure of the business.

The appointment is contingent on obtaining AIFM approval, expected to be achieved within Q2, and the execution of the new IMA. The appointment of Aberdeen Standard Gresham House as Investment Manager is expected to become effective in Q2 2020.

– Ends –

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) NO 596/2014.

For more information contact:
Gresham House plc   Tony Dalwood, Chief Executive Officer Kevin Acton, Chief Financial Officer	+44 (0)20 3837 6270
Houston – PR advisors   Alexander Clelland Anushka Mathew	[email protected] +44 (0)20 3701 7660
Canaccord Genuity Limited – Nominated Adviser and Joint Broker   Bobbie Hilliam Georgina McCooke	+44 (0)20 7523 8000
Jefferies International Limited – Joint Broker   Paul Nicholls Max Jones	+44 (0)20 7029 8000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTJRMFTMTTTMAM

Close

×

RNS Number : 4551H

N4 Pharma PLC

25 March 2020

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR").

 

25 March 2020

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

Covid-19 Project Update and operational update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that it will be undertaking a proof of concept research project using a Covid-19 DNA plasmid for the purpose of demonstrating the ability of Nuvec® to be used as a delivery system by potential collaboration partners developing Covid-19 DNA or RNA vaccines.

 

Nuvec® is a silica nanoparticle with elongated silica spikes radiating from the core.  This topography results in a high surface area which subsequently is coated with Polyethylenimine ("PEI"), resulting in a positively charged surface. It has been previously demonstrated that oligonucleotides including plasmid DNA and mRNA can be attached to the nanoparticle at high loading capacity. In both in vitro and in vivo test models, the loaded nanoparticle is taken up by cells involved in transfection/transduction processes resulting in the synthesis of foreign proteins and stimulation of the required immunological response.

The proof of concept work will show whether Nuvec® is capable of loading the Covid-19 plasmid and transfecting cells with the plasmid in vitro. Assuming successful in vitro transfection, the Company will then undertake a proof of concept in vivo study to demonstrate the improved transfection when using Nuvec ®, compared to not using the delivery system, by measuring the production of the antigenic protein and antibodies generated against the encoded Covid-19 protein.

The Covid-19 DNA plasmid will be licensed from the National Institute for Health (NIH) in the USA and is the same plasmid provided to leading biotech companies and researchers already working on Covid-19 vaccines. The Company will appoint an experienced contract research organisation (CRO) that it has worked with previously to undertake the program of studies outlined above. Further details on timings will be notified as soon as they are available. It is important to note that N4 Pharma is not itself attempting to develop a vaccine for coronavirus, it is purely seeking to demonstrate whether Nuvec ® could work as a delivery system for a vaccine when it is developed.

 

Operational impact of Covid-19 pandemic

 

The Company operates a virtual model, so most of its workforce typically either work from home or in small offices. Therefore, operationally, the Company has not been affected to date by the UK Government's requirements regarding social distancing and self-isolation.

 

Further, the Company has received confirmation that the main laboratories contracted by N4 Pharma to undertake research and those identified as partners for the Covid-19 work detailed above are implementing rota systems to enable key laboratory staff to stay and work on projects. As a result, there are no current significant delays to N4 Pharma's announced work plan. This will be kept under close review in the coming months, as the situation evolves.

 

The Company's academic partner in Australia remains open, meaning N4 Pharma currently has a continued supply of Nuvec ® for its research needs.

 

On 20 March 2020, the Company's academic partner in the UK announced it will be closed until after Easter. As this is a longer-term project, looking at stability testing and efficacy proof of concept of a DNA plasmid loaded on Nuvec® the Company does not expect this closure to greatly impact their program of work.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"Developing a convincing proof of concept data package for Nuvec® is a key priority for the Company so demonstrating whether Nuvec® is capable of loading a plasmid DNA for the Coronavirus provides an opportunity to show the versatility and potential for our Nuvec® delivery system, and to license Nuvec® to partners looking to develop vaccines for this virus.

 

We are not doing this work to develop a vaccine for Coronavirus but rather to demonstrate to those working on these vaccines how Nuvec® may enhance any vaccine and could be beneficial for subsequent vaccines they may be looking to develop for this Coronavirus or other viruses that may well surface in the future."

 

 

Enquiries:

 

N4 Pharma Plc Nigel Theobald, CEO	Via Scott PR
Allenby Capital Limited James Reeve/Asha Chotai	Tel: +44(0)203 328 5656
Scott PR Georgia Smith	Tel: +44(0)1477 539 539

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

UPDJIMRTMTMTBPM

Close

×

RNS Number : 3538G

British Honey Company PLC (The)

17 March 2020

 

17 March 2020

The British Honey Company

("BHC" the "Company")

 

HMRC authorisation to produce denatured alcohol

 

The British Honey Company, the premium British Honey and Infused Spirits brand, announces that it has received permission from HMRC to produce denatured alcohol and will now utilise its excess capacity to produce alcohol sanitisers at its distillery following a national shortage of alcohol based sanitiser products caused by the spread of Covid-19, coronavirus.

Additional capacity at the BHC distillery in Worminghall, Buckinghamshire, will be immediately used to make the alcohol sanitiser, with products expected to be available this week.  The specially formulated product is made with 70% alcohol and extracts of British Honey and Green Tea.

Michael Williams, Chief Executive Officer of BHC, commented: "An alcohol based sanitiser is vodka or gin at 70 percent ABV made from denatured alcohol.  Following approval of our application to HMRC to produce denatured alcohol, our expert distillery team have been working alongside our in-house microbiologist and an Oxford University chemist to develop and manufacture this new product.

"The Company will continue to produce its vodka, gin and rum products as the alcohol market moves to online sales in the current environment. BHC is making the product available online. Being able to produce such an in demand product within our existing capabilities enhances our existing business model at the same time as assisting with the efforts to combat the spread of Covid-19."

 

Enquiries:

The British Honey Company	Tel: +44 (0)80 0368 7612
Michael Williams, Founder and CEO
Cairn Financial Advisers LLP (Aquis Stock Exchange Corporate Adviser)	Tel: +44 (0)20 7213 0880
Jo Turner / Liam Murray / Mark Rogers
Stanford Capital Partners (Broker)	Tel: +44 (0)20 3815 8880
Patrick Claridge / John Howes / Bob Pountney
IFC Advisory (PR)	Tel: +44 (0)20 3934 6630
Graham Herring / Florence Chandler

 

For further information, visit: www.britishhoney.co.uk

 

Notes to Editors

The British Honey Company is a UK based producer of spirits, honey and jams. It began trading in November 2014 initially focused on honey production and, later, expanding into honey infused spirits. The Company currently produces 13 honey products and 16 spirits including gin, vodka, rum and whiskey, many of which have won awards in the UK and abroad. These products are produced and stored in the Company ' s facilities in Worminghall, Buckinghamshire.

 

The Company ' s facilities provide it with a scalable platform from which the Directors plan to expand operations through organic growth and acquisition both in the UK and abroad. The Company has invested significantly in its infrastructure which includes, inter alia , a fully operational distillery with an electronic, computer-controlled, 1,000-litre capacity still and a bottling facility capable of processing the equivalent of approximately 1.5 million bottles per year. Further, the Company has developed proprietary software to manage the manufacturing process and sales which allows the Company, among other things, to trace single ingredients through to individual bottles of spirits or jars of honey. This meticulous approach has earned the Company accreditations from the Soil Association, for organic food certification, and from SALSA, for food safety. The Directors believe SALSA certification has only been awarded to approximately 39 producers of gin, vodka and whiskey in the UK.

 

As well as producing the Keepr ' s brand spirits, the distillery is an accredited, HMRC compliant, bonded warehouse for the storage of its own and third-party products. The Directors believe this provides the Company with significant financial and logistical advantages over many craft distilleries whilst also allowing it to provide an end-to-end distillation and bottling service to third party brands which it can do so within its existing spare capacity.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NEXFLFSRVAIRLII

Close